Diabetic Foot Ulcer Treatment Market to Grow at a CAGR of 7.01% from 2026 to 2034; Rising Incidence of DFUs is Propelling Market Growth

The global diabetic foot ulcer treatment market size was valued at USD 7.14 billion in 2025. The market is expected to grow from USD 7.53 billion in 2026 to USD 12.46 billion by 2034, exhibiting a CAGR of 6.5% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Diabetic Foot Ulcer Treatment Market Size, Share & Industry Analysis, By Ulcer Type (Neuropathic Ulcers, Ischemic Ulcers, and Neuro-Ischemic Ulcers), By Product (Wound-Care Dressings [Antimicrobial Dressings, Foam Dressings, and Hydrogel Dressings], Wound-Care Devices [Negative Pressure Wound Therapy, Ultrasound Therapy, and Hyperbaric Oxygen Therapy], and Active Therapies [Skin Grafts & Substitutes and Growth Factors]), By Severity (Mild, Moderate, and Severe), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Homecare Settings, and Others), and Regional Forecast, 2026-2034”.

Diabetic Foot Ulcers (DFUs) are chronic wounds that affect individuals with both type 1 and type 2 diabetes. They represent a serious complication of diabetes and are generally characterized by wounds on the feet that heal slowly or fail to heal completely. Without timely and effective treatment, DFUs may progress to severe infections and, in advanced cases, result in lower-limb amputation. DFU care encompasses a broad spectrum of treatment products and therapies designed to promote wound healing, prevent infection, and reduce ulcer-related complications. These include advanced wound dressings such as antimicrobial & hydrogel dressings and devices such as negative pressure wound therapy (NPWT), Hyperbaric Oxygen Therapy (HBOT), and active therapies such as skin graft substitutes. Offloading devices are also widely used to minimize pressure on affected areas and support healing. The rising prevalence of DFUs among the growing diabetic population is expected to increase demand for these treatment solutions, thereby supporting market expansion.

Convatec Announced Completion of a Significant Multi-year Expansion at Its Rhymney  Production Unit

In July 2026, Convatec, a renowned medical product and technology company specializing in solutions for the management of chronic conditions, announced the successful completion of a multi-year expansion project at its manufacturing facility in Rhymney, South Wales. The company invested more than USD 27.1 million in the expansion, aimed at strengthening the site’s manufacturing capabilities and supporting the growing demand for advanced healthcare products.

Growing Prevalence of Diabetes Fosters Market Growth

The mounting diabetes burden globally is a primary factor driving the increasing incidence of diabetic foot ulcers, one of the most serious complications associated with the disease. The expanding geriatric population, sedentary lifestyles, dietary changes, and rising obesity rates are contributing to the global diabetes burden. Moreover, clinical evidence indicates that individuals with diabetes are substantially more likely to develop foot ulcers than non-diabetic individuals, further intensifying the need for effective treatment options.

For instance, an article published in the International Wound Journal in 2023 reported that diabetic foot ulcers have a global prevalence of approximately 6.3% based on available studies assessing their global epidemiology.

Technological innovations in diabetic foot ulcer treatment management are encouraging the development and uptake of smart wound dressings. Leading companies are increasing their investments in R&D to introduce innovative products with enhanced monitoring and healing capabilities, thereby supporting the global diabetic foot ulcer treatment market growth.

On the other hand, the low rates of wound diagnosis and treatment across emerging countries are impeding diabetic foot ulcer treatment demand.

Major Players Emphasize Product Portfolio Expansion to Support Their Dominance

Leading diabetic foot ulcer treatment companies are maintaining their market dominance through broad product portfolios, strategic acquisitions, collaborations, and other inorganic growth initiatives implemented across various regions. Smith+Nephew and Solventum hold prominent positions in the market, driven by their extensive offerings and strong global footprint. In addition, the rising emphasis on  R&D is encouraging companies to launch technologically advanced and differentiated wound care products, thereby strengthening their market presence.

• In April 2024, Smith+Nephew introduced its RENASYS EDGE Negative Pressure Wound Therapy (NPWT) System in the U.S., providing a patient-focused option for managing chronic wounds.

List of Key Players Mentioned in the Report

• Coloplast A/S (Denmark)
• Smith+Nephew (U.K.)
• Solventum (U.S.)
• Convatec Inc. (U.K.)
• Integra LifeSciences (U.S.)
• Braun SE (Germany)
• Cardinal Health (U.S.)
• Mölnlycke Health Care AB (Sweden)
• Essity Aktiebolag (publ). (Sweden)
• MIMEDX Group, Inc. (U.S.)

Key Industry Development

• April 2024: Smith+Nephew reported that the U.K. National Institute for Health and Care Excellence (NICE) reviewed its PICO Single Use Negative Pressure Wound Therapy System (sNPWT). NICE concluded that the system delivers improved clinical outcomes compared with standard dressings in decreasing the risk of surgical site infections.

Further Report Findings

• North America maintained its position as the leading regional market, reaching USD 2.65 billion in 2024 and increasing to USD 2.78 billion in 2025. The widespread adoption of advanced wound-care products, well-developed hospital infrastructure, and rising healthcare expenditure supports the region’s strong market position.
• Europe is predicted to expand at a CAGR of 6.2% over the forecast period, representing the second-fastest growth among regions, and is projected to reach USD 2.05 billion in 2026. Increasing diabetic population, combined with the region’s advanced healthcare infrastructure, is anticipated to accelerate market expansion.
• Based on ulcer type, neuro-ischemic ulcers accounted for the largest diabetic foot ulcer treatment market share in 2025. The rising incidence of neuro-ischemic ulcers among diabetic patients is increasing the need for specialized treatment solutions. Furthermore, the introduction of innovative wound-care products, skin substitutes, and NPWT technologies by prominent companies is likely to create additional growth opportunities for this segment.
• By product, wound-care dressings led the market in 2025 due to their effectiveness and versatility in managing DFUs. Leading producers are intensifying R&D efforts to develop more advanced dressing technologies, providing further momentum to the segment.

Table of Segmentation